Andreas Axén

Title: Inventor Profile: Andreas Axén

Introduction

Andreas Axén is a notable inventor based in Uppsala, Sweden, with a diverse portfolio of innovations, particularly in the fields of biotechnology and bioprocess control. With a total of four patents to his name, his contributions significantly impact the efficiency and functionality of bioprocessing and separation technologies.

Latest Patents

Andreas Axén's latest patents reflect his commitment to advancing biotechnological methods. One of his significant inventions is a **Method for Control of a Bioprocess**. This computer-implemented method utilizes a controller configured to manage a bioprocess in a bioreactor. The method involves obtaining measurement results through spectrophotometry of a bioprocessing fluid, generating control parameters based on these results and a specified model, and subsequently controlling the bioprocess through the generated parameters.

Another noteworthy invention is the **Use of Urea Variants as Affinity Ligands**. This innovation centers around an IgG-binding compound that specifically binds to human IgGs of k-type and their functional derivatives. The compound features an N,N-alkylated urea moiety situated between an aromatic segment and a linear or cyclic aliphatic group. This binding is crucial as it targets a unique pocket-shaped binding site on all human IgG k-Fabs, positioned between the CH1 and CL domains of their constant part. This invention also proposes a separation matrix for affinity chromatography leveraging this compound, highlighting its versatility and applicability in biochemical separations.

Career Highlights

Throughout his career, Andreas has worked with distinguished organizations such as GE Healthcare Bio-Sciences AB and Amersham Biosciences AB. His roles in these companies allowed him to explore and develop groundbreaking technologies within the realm of bioprocessing and separation methods, solidifying his reputation as a skilled inventor.

Collaborations

Andreas has collaborated with esteemed colleagues in his field, including Lars C Andersson and Tesfai Gebru. These partnerships have likely contributed to his innovative outputs and furthered advancements in their shared research interests.

Conclusion

In conclusion, Andreas Axén stands out as a key figure in the realm of biotechnology innovation. His patent contributions, particularly in bioprocess control and affinity ligand methodologies, reflect his dedication to advancing industry practices and enhancing the efficacy of bioprocessing. As he continues to pave the way for future developments, his work remains an essential part of the ongoing evolution in biotechnology.